Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study
Authors:
- Naomi GronichNGNaomi Gronich
- Idit LaviILIdit Lavi
- Gad RennertGRGad Rennert
Open Access
- 7 November 2011
- journal article
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 183 (18) , E1319-E1325
Abstract
Background: Combined oral contraceptives are a common method of contraception, but they carry a risk of venous and arterial thrombosis. We assessed whether use of drospirenone was associated with an increase in thrombotic risk relative to third-generation combined oral contraceptives. Methods: Using computerized records of the largest health care provider in Israel, we identified all women aged 12 to 50 years for whom combined oral contraceptives had been dispensed between Jan. 1, 2002, and Dec. 31, 2008. We followed the cohort until 2009. We used Poisson regression models to estimate the crude and adjusted rate ratios for risk factors for venous thrombotic events (specifically deep vein thrombosis and pulmonary embolism) and arterial thromboic events (specifically transient ischemic attack and cerebrovascular accident). We performed multivariable analyses to compare types of contraceptives, with adjustment for the various risk factors. Results: We identified a total of 1017 (0.24%) venous and arterial thrombotic events among 431 223 use episodes during 819 749 woman-years of follow-up (6.33 venous events and 6.10 arterial events per 10 000 woman-years). In a multivariable model, use of drospirenone carried an increased risk of venous thrombotic events, relative to both third-generation combined oral contraceptives (rate ratio [RR] 1.43, 95% confidence interval [CI] 1.15–1.78) and second-generation combined oral contraceptives (RR 1.65, 95% CI 1.02–2.65). There was no increase in the risk of arterial thrombosis with drospirenone. Interpretation: Use of drospirenone-containing oral contraceptives was associated with an increased risk of deep vein thrombosis and pulmonary embolism, but not transient ischemic attack or cerebrovascular attack, relative to second- and third-generation combined oral contraceptives.Keywords
This publication has 27 references indexed in Scilit:
- Types of progestogens in combined oral contraception: effectiveness and side-effectsCochrane Database of Systematic Reviews, 2011
- Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims dataBMJ, 2011
- Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research DatabaseBMJ, 2011
- Hormonal contraception and risk of venous thromboembolism: national follow-up studyBMJ, 2009
- Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral ContraceptivesObstetrics & Gynecology, 2007
- Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetateJournal of Thrombosis and Haemostasis, 2004
- Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) StudyStroke, 2002
- Oral Contraceptives and the Risk of Venous ThrombosisNew England Journal of Medicine, 2001
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control studyThe Lancet, 1995